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Monitoring hypoxia and vasculature during
bevacizumab treatment in a murine colorectal
cancer model
L. Heijmena*, E. G. W. ter Voertb, C. J. A. Puntc, A. Heerschapb,
W. J. G. Oyend, J. Bussinke, C. G. J. Sweepf, P. Lavermand, P. N. Spane,
L. F. de Geus-Oeid, O. C. Boermand and H. W. M. van Laarhovena,c
The purpose of this study was to assess the effect of bevacizumab on vasculature and hypoxia in a colorectal tumor
model. Nude mice with subcutaneous LS174T tumors were treated with bevacizumab or saline. To assess tumor
properties, separate groups of mice were imaged using 18F-Fluoromisonidazole (FMISO) and 18F-Fluorodeoxyglucose
(FDG) positron emission tomography or magnetic resonance imaging before and 2, 6 and 10days after the start of
treatment. Tumors were harvested after imaging to determine hypoxia and vascular density immunohistochemically.
The T2* time increased signiﬁcantly less in the bevacizumab group. FMISO uptake increased more over time in the
control group. Vessel density signiﬁcantly decreased in the bevacizumab-treated group. The Carbonic anhydrase
9 (CAIX) and glucose uptake transporter 1 (GLUT1) fractions were higher in bevacizumab-treated tumors. However,
the hypoxic fraction showed no signiﬁcant difference. Bevacizumab led to shorter T2* times and higher GLUT1 and
CAIX expression, suggesting an increase in hypoxia and a higher glycolytic rate. This could be a mechanism of
resistance to bevacizumab. The increase in hypoxia, however, could not be demonstrated by pimonidazole/FMISO,
possibly because distribution of these tracers is hampered by bevacizumab-induced effects on vascular permeability
and perfusion. Copyright © 2014 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Bevacizumab (Avastin®) is an antibody against vascular endothe-
lial growth factor (VEGF), inhibiting VEGF stimulated angiogene-
sis (1). In advanced colorectal cancer, bevacizumab has been
shown to increase progression-free survival, when combined
with cytotoxic treatment (2–5). The exact mechanism of action
of bevacizumab has not yet been clariﬁed, nor are mechanisms
of resistance to bevacizumab understood. It has been suggested
that bevacizumab leads to vascular normalization of tumor
vessels, thereby increasing delivery of cytotoxic agents to the
tumor and thus improving treatment efﬁcacy (6,7). In contrast,
other hypotheses claim that bevacizumab may lead to the
formation of inadequate tumor vessels, inducing tumor hypoxia
and necrosis (8). Although inadequate vasculature and tumor
hypoxia may subsequently lead to tumor necrosis, induction of
hypoxia could also drive progression toward a more aggressive
tumor phenotype (9,10). Hypoxic tumors are less responsive to
systemic therapy and radiation therapy (11,12). This could
explain the suboptimal results of bevacizumab treatment in
various cancer types, including breast cancer (13–15). The
suboptimal results have recently led to withdrawal of US Food
and Drug Administration approval for the use of bevacizumab
in combination with paclitaxel in metastatic breast cancer (16).
In this study we aim to assess the biological effects of
bevacizumab over time in a colorectal cancer model. Func-
tional imaging techniques were used to assess the biological
effects of bevacizumab on hypoxia and functional vasculature,
since these in vivo measurements provide the opportunity for
repeated measurements and can also be implemented in
clinical studies.
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18F-Fluoromisonidazole (FMISO) is a nitro-imidazole derivative,
which is reduced into intermediary metabolites by intracellular
enzymes at low intracellular pO2. After bioreduction, FMISO
(metabolites) are trapped in hypoxic cells, allowing for positron
emission tomography (PET) imaging of hypoxic tumors (17).
Thus, FMISO PET is sensitive to hypoxia and, therefore, could
provide an answer to whether treatment with bevacizumab
increases tumor hypoxia. However, no FMISO PET data after
bevacizumab treatment are available.
18F-Fluorodeoxyglucose (FDG) PET is sensitive to changes in
tumor glucose metabolism over time. FDG uptake depends on
expression of GLUT1, the main glucose and FDG transporter,
and the presence and activity of the enzyme hexokinase. FDG
uptake is also dependent on tumor vascularity for supply of
FDG and might be inﬂuenced by tumor hypoxia owing to the
Pasteur effect (18,19). However, tumors often exhibit enhanced
glycolysis under normoxic conditions (Warburg effect) for ATP
production. FDG PET has been shown to have predictive value
for response to several cytostatic treatments (20), including
bevacizumab-containing treatments (21–23).
In contrast to FDG PET, dynamic contrast enhanced magnetic
resonance imaging (DCE-MRI) is a direct measurement of
functional vasculature. Various DCE-MRI parameters, such as
the area under the contrast–concentration curve (AUC), blood
volume, K trans and kep have been shown to change after
administration of antiangiogenic or antivascular drugs (21,24,25).
Similarly, T2* MRI can be used to assess vascular properties, without
the requirement for the administration of contrast agents. T2* MR
contrast arises from local inhomogeneities of the magnetic ﬁeld
mainly owing to the tissue level of blood deoxyhemoglobin (26).
Therefore, T2* measurements are dependent on hypoxia, blood
ﬂow and blood volume (27).
In this study, we assessed the effect of bevacizumab on func-
tional imaging parameters with FMISO PET, FDG PET, DCE-MRI
and T2* at different time points after start of treatment, to assess
whether bevacizumab increases hypoxia owing to a disruption
of tumor vasculature. Immunohistochemical analyses were used
to corroborate our results.
2. MATERIALS AND METHODS
2.1. Animals
Seventy female BALB/c nu/nu mice of 19-24 grams and 6–8weeks
of age were purchased from Janvier (Uden, the Netherlands). Mice
were allowed to adapt for one week after transport and were held
in a controlled environment in accordance with institutional guide-
lines (temperature 22 °C, humidity 61%, 12 h light–dark cycle, in
individually ventilated cages). Food and water were supplied ad
libitum.
Mice were injected subcutaneously, just above the rights
scapula, with ~1 × 106 cells of the bevacizumab-sensitive human
colon cancer cell line LS174T (CCL-188; passage 7; American
Type Culture Collection, Manassas, VA, USA). After 14 days,
tumors had grown to a maximum diameter of 0.4–0.8 cm and
treatment was started. Animals were divided into four groups:
two experimental groups undergoing MR and PET imaging,
respectively; and two control groups undergoing MR and PET
imaging. For each day of imaging, a separate group of mice
was used, except for the sequential PET imaging days. In order
to reduce the burden of repetitive anesthesia for each mouse,
to make sure overall drop out was low and measurements were
reliable, separate groups of ﬁve mice were used for PET and MR
imaging on each day (Fig. 1). All experiments were approved by
the Animal Welfare Committee of the Radboud University
Medical Centre.
2.2. Treatment
In the experimental group, bevacizumab (Avastin®, Roche
Pharma, Germany) was administered twice a week (during
10 days) by intraperitoneal injection in a dose of 5mg/kg. The
control group received an intraperitoneal injection with 0.9%
saline at the same time points.
2.3. Imaging
PET imaging was performed on an preclinical PET scanner
(Inveon, Siemens USA Inc., Knoxville, TN, USA). FMISO PET imag-
ing was performed before treatment and 1, 5 and 9 days after
the start of bevacizumab therapy. FDG PET imaging was
performed before treatment and 2, 6 and 10 days after the start
of bevacizumab therapy (Fig. 1). Before FDG PET imaging, mice
fasted for 12 h. Ten min before administration of FDG, mice were
anesthetized with isoﬂurane 4% for induction and 1.5-2% for
maintenance. A 60min interval between injection of FDG and
FMISO and the start of the PET scan was used. All PET scans were
performed using 20min single-bed position measurements.
Mice were injected intravenously in an inserted tail vein cannula
with a solution of approximately 10MBq of the radiotracer in
0.2ml 0.9% saline. Images were reconstructed using OSEM-
3D-MAP reconstruction. The highest standardized uptake values
(SUVmax) for both FMISO and FDG PET were recorded for each
tumor, by drawing a region of interest around the entire tumor. In
general, SUVmax demonstrates a larger change after start of treat-
ment than SUVmean. Therefore, the SUVmax values are reported.
MR imaging was performed on a 7 T small animal MR scanner
(Clinscan, Bruker Biospin, Ettlingen, Germany) using a Bruker rat
brain receiver coil. Imaging was performed at baseline and 2, 6
and 10 days after start of therapy.
DCE-MRI was performed using a T1 weighted fast low-angle
shot sequence. Sequence parameters were as follows: repetition
time (TR) 90ms, echo time 1.82ms, ﬂip angle 15°, 16 slices with a
thickness of 1mm, ﬁeld of view 30mm, matrix size 64 × 64.
After approximately 6 s, 0.2ml (0.02mmol/ml) of the contrast
agent Gadomer-17 (Schering AG, Berlin, Germany) was injected
in the tail vein cannula.. Before and after DCE-MRI, proton density
images were recorded with the same sequence parameters as
the DCE-MRI except for the ﬂip angle of 20° and TR 1500ms. Data
from these images were combined with the DCE-MRI data to
calculate the concentration of Gadomer-17, using the method
described by Hittmair et al. (28). Area under the concentration peak
was calculated for 0–90 and 0–180 s after contrast injection.
T2* imaging was performed with a gradient echo sequence,
with a TR of 1000ms and six different echo times (TE): 2.78,
4.86, 6.89, 8.92, 10.95 and 12.98ms. Eighteen 1mm slices were
obtained with two averages. T2* calculated maps were gener-
ated using in-house built software based on Matlab (MathWorks,
Natick, MA, USA). The data were ﬁtted pixel-by-pixel to a mono-
exponential curve SI = Aρexp(TE/T2*)+B where ρ is the proton
density, TE is the echo time, and the parameter of interest T2*,
the relaxation time. The regions of interest for the MR images
were manually drawn on T2 images and copied onto the T2*
map and contrast concentration images.
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2.4. Immunohistochemistry
To correlate in vivo hypoxia and vasculature measurements with
ex vivomeasurements, all mice were euthanized immediately after
the last scan. Respectively 50–80 and 2min before death, the
hypoxic marker pimonidazole {80mg/kg in 0.1ml; 1-[(2-hydroxy-
3-piperidinyl) propyl]-2-nitroimidazole hydrochloride; Natural
Pharmacia International, Research Triangle Park, NC, USA} and
the perfusionmarker Hoechst 33342 (Sigma Chemical Co., St Louis,
MO, USA) were administered. Tumors were removed and snap-
frozen in liquid nitrogen. They were stored at 80 °C.
Tumor sections (4μm) were ﬁxed in acetone at 4 °C for 10min
and washed with phosphate buffered saline (PBS). The sections
were incubated overnight at 4 °C with a rabbit anti-pimonidazole
(gift from J. A. Raleigh, Department of Radiation Oncology,
University of North Carolina School of Medicine, Chapel Hill,
NC, USA) in primary antibody diluent (1:1000; PAD, Abcam,
Cambridge, UK). Sections were rinsed three times with PBS. To
stain the vasculature, undiluted 9F1 (rat anti-mouse endothe-
lium, Department of Pathology, Radboud University Medical
Center) was applied to the slides for 45min at 37 °C.
To extend our data concerning hypoxia and functionality of
the vessels after bevacizumab treatment, all tumors harvested
on day 10 were stained for CAIX and glucose uptake transporter
1 (GLUT1). Sections were pre-incubated for 30min in 5% normal
donkey serum in PAD. CAIX was stained by applying rabbit anti-
CAIX-biotin (Novus Biologicals NB100-417B; 1:500 in PAD)
overnight at 4 °C followed by mouse anti-biotin-Alexa4888
(1:200 in PAD) for 30min at 37 °C. GLUT1 was stained using
rabbit anti-GLUT1 (Neomarkers; 1:100 in PAD) overnight at 4 °C
and goat anti-rabbit-Cy3 (1:600 in PBS) for 30min at 37 °C. In
between, sections were rinsed three times with PBS. Sections
were mounted in Fluorostab.
Using a ﬂuorescence microscope (Axioskop, Zeiss, Göttingen,
Germany), all stained sections were digitalized using a computer-
controlled motorized stepping stage system. By means of Image
Processing Laboratory software (Scanalytics Inc., Fairfax, VA, USA),
the tumor area was drawn, excluding necrotic areas. The fraction
of positive staining in the total tumor area was calculated, provid-
ing the hypoxic fraction (fraction of pimonidazole positive staining)
and vascular density (number of vessels within 1mm2) (29).
Figure 1. Schedule of imaging and sacriﬁce of the mice.
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2.5. ELISA procedure for bevacizumab
Bevacizumab concentration in plasma was measured with a one-
site enzyme-linked immunosorbent assay (ELISA). In short, 96-well
plates (Greiner Bio-One, Alphen a/d Rijn, the Netherlands) were
coated overnight at 4 °C with 100μl VEGF (0.50μg/ml, Genentech
Inc, San Francisco, CA, USA), washed (96PW plate washer, Tecan
Group Ltd, Männedorf, Switzerland), and then blocked with
150μl Superblock (Pierce, Rockford, IL, USA) for 30min at ambient
temperature, washed and further blocked with 300μl bovine
serum albumin (Sigma Chemical, St Louis, MO, USA) for 4 h at
ambient temperature. Subsequently, the plate was washed and
standards (range 0–10ng/ml Avastin, Roche, Basel, Switzerland),
study samples and a reference sample were placed into the wells;
the plate was incubated overnight at 4 °C. After washing, the plate
was incubated with 100μl Mouse anti-Human IgG (Fc) peroxidase
(dilution 1:25,000, SouthernBiotech, Birmingham, UK) for 2 h at
ambient temperature, again washed and incubated with 100μl
ready-to-use tetramethyl benzidine solution (Kem-En-Tec,
Taastrup, Denmark) for 15–20min for color development. The
reaction was terminated by addition of 0.5 M H2SO4 and optical
density wasmeasured at 450 nm in aMultiskan Ascent plate reader
(Lab Systems, Oy, Helsinki, Finland). The analytical sensitivity,
deﬁned as the minimum bevacizumab concentration evoking a
response signiﬁcantly different from that of the zero calibrator,
was 16pg/ml. Plasma samples, diluted 4000–24 000 fold, exhibited
excellent linearity. Known quantities of bevacizumab were added
to six plasma samples. The recoveries in the plasma samples
ranged from 87 to 110% with a mean recovery of 98%. In each
run the reference preparation, prepared from a pool of plasma
from animals treated with bevacizumab, was used to monitor the
long-term performance of the assay. The concentration in the
reference preparation was 1670ng/ml, the within-run coefﬁcient
of variation (CV) and the between-run CV were 7.0 and 10.0%,
respectively.
2.6. Statistical analyses
To compare the course of changes in the parameters over time
between the bevacizumab and control group, linear regression
analysis was used. Linear regression analysis assessed the effect
of treatment over time on hypoxia and vasculature. We assessed
the interception of the lines of the bevacizumab and control
groups at day 0. When the lines did not intercept at day 0, we
started linear regression analyses from day 1 (start of treatment).
This method of analysis was used to accommodate a ﬂare-up in
(PET) parameters directly after start of treatment. This ﬂare-up
directly after start of treatment has been described by Findlay
et al. (30). If the lines did intercept, the regression analyses were
started at the baseline measurements. The difference in the course
of the measurement parameters over time in the bevacizumab
and control groupwas expressed in a standard coefﬁcient β. Linear
regression analysis was also used to assess whether parameters
changed in time independent of treatment. A Student t-test
was used to test for differences between control and treatment
groups at the last time point, since the differences were expected
to be largest at the last measurement. Furthermore, a Student t-test
was used to compare CAIX and GLUT1 staining at the same time
point. A Pearson correlation was used to assess correlations
between image parameters and histopathology results. p-Values
0.05 were considered to be statistically signiﬁcant. All data were
analyzed using SPSS 16.0 (SPSS inc, Chicago, IL, USA).
3. RESULTS
3.1. Tumors
In 69 of the 70 mice, subcutaneous tumor growth was observed.
Therefore, 34 mice were imaged with FMISO and FDG PET and
35 mice with MRI, leaving only four mice in the intervention group
at day 9 and 10, measured with PET. All other groups contained
ﬁve mice. Tumor volume (measured with MR) increased over time
(r=0.46, p< 0.01). The average tumor volume before the start of
treatment was 310±156mm3, while the average volume 10days
after the start of treatment was 420±137mm3 for the intervention
group and 783±179mm3 for the control group. The increase in
tumor volume was signiﬁcantly larger in the untreated control
group compared with the bevacizumab group (standardized
coefﬁcient β 0.62, p=0.01; Fig. 2).
3.2. Imaging
FMISO particularly accumulated in the center of the tumor, while
FDG uptake was mainly observed at the tumor rim (Fig. 3). FMISO
uptake in the tumor as measured by SUVmax steadily increased
over time from 0.67 g/cm3 before treatment to 1.43 g/cm3 at day
9 in the control group. In the bevacizumab group, the SUVmax
increased from 0.67 g/cm3 before treatment to 1.25g/cm3 at day
1, but thereafter decreased to 0.91 and 0.88 g/cm3 at days 5 and
9, respectively (Fig. 4A). Regression analysis beginning at the start
of treatment showed a signiﬁcant difference in the course of
FMISO uptake between the treated group and the control group,
with less hypoxia in the treated group (standardized coefﬁcient
β 0.85, p=0.04). At day 10, there was a trend toward a differ-
ence between the bevacizumab-treated and control group
(0.88 vs 1.43 g/cm3, p= 0.07).
In the control group, the average SUVmax of FDG increased
from 0.53 g/cm3 before treatment to 1.08 g/cm3 at day 2 and
then remained stable. In contrast, in the bevacizumab-treated
group SUVmax of FDG increased on day 2 (1.22 g/cm
3), but
decreased again at day 6 and at day 10 (day 6, 1.04 g/cm3;
day 10, 0.88 g/cm3; Fig. 4B). With linear regression analysis,
no signiﬁcant difference was observed in the course of FDG
Figure 2. Box plot of the mean tumor volume. The increase in tumor
volume was signiﬁcantly less pronounced in the bevacizumab group
(β 0.62, p< 0.01).
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uptake between the two groups. However, after 10 days the
FDG uptake was signiﬁcantly lower in the bevacizumab-treated
group (average SUVmax 0.88 vs 1.10 g/cm
3, p= 0.05). A positive
correlation between FDG PET SUVmax and FMISO PET SUVmax
values was observed (r = 0.52, p=<0.01).
On DCE-MRI, the AUC90 and the AUC180 decreased over time
in both the bevacizumab-treated and the control group. No
signiﬁcant differences were observed between the two groups,
either over time (linear regression analysis) or at the last mea-
surement (Student’s t-test; Fig. 4C). However, the area under
the contrast–concentration curve was signiﬁcantly lower in
larger tumors (for AUC180, r =0.45, p= 0.02; for AUC90,
r =0.44, p= 0.02).
The T2* value of the tumors increased over time from an aver-
age of 3.9ms before treatment to 7.0ms on day 10. The rise was
more prominent in the control group than in the bevacizumab
group (standardized coefﬁcient 0.45, p= 0.01). However, there
was a large spread in the measurements (Fig. 4D). After 10 days,
a trend for a lower average T2* value was observed in the
bevacizumab-treated mice compared with the control group
(T2* at day 10: 5.14 vs 8.94ms; p= 0.09).. The T2* value correlated
to the size of the tumor (r = 0.68, p< 0.01) in both the treated
and untreated tumors.
3.3. Immunohistochemical assessment of tumor hypoxia
and vascular density
A typical image of the hypoxia, perfusion and vessels in the colo-
rectal tumor is shown in Fig. 5. The hypoxic areas were well
perfused with Hoechst (blue) and high vascular density (red), but
areas are overlapping, indicating regions with acute hypoxia:
perfused, Hoechst-positive areas that are hypoxic (pimonidazol
positive, green). The average hypoxic fraction in the LS174T tumors
was 0.38 and did not signiﬁcantly change over time. Furthermore,
no difference in hypoxic fraction was observed between the
treated and the control group.
In contrast, CAIX and GLUT1, metabolic markers that are asso-
ciated with hypoxia, were signiﬁcantly higher in bevacizumab-
treated tumors 10 days after start of treatment (0.22 vs 0.09, p
0.01 and 0.10 vs 0.05, p= 0.05; Fig. 6). Before the start of
treatment, the average vascular density was 100.7 vessels/mm2.
Vascular density signiﬁcantly decreased over time in the
bevacizumab-treated group compared with the control group
(β 0.25, p= 0.05). After 10 days of treatment, the vascular
density was 74.5 ± 25.4 vessels/mm2 in the bevacizumab-treated
group and 110 ± 36.0 vessels/mm2 in the control group. There
was a signiﬁcant negative correlation between vascular density
Figure 3. (A) Examples of FDG PET scans showing a treated and untreated tumor, both with high uptake in the rim. The heart and bladder also
showed a high FDG uptake. (B) FMISO PET scans showing high FMISO uptake in the center of the tumors, but also high uptake in the intestine
and bladder. (C) Dynamic contrast enhanced images and (D) a T2* maps of a treated and untreated mouse. The tumor borders are marked with
a red line.
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and CAIX expression (r =0.56, p= 0.02) and a signiﬁcant
positive correlation between CAIX and GLUT1 expression
(r = 0.57, p= 0.01).
Vascular density was positively correlated to AUC180 (r = 0.41
p= 0.03). The average perfused fraction in the tumors was 0.41
and this parameter was unaffected by time or treatment. The per-
fused fraction did not signiﬁcantly correlate with vascular density.
3.4. Bevacizumab plasma levels
No bevacizumab was detectable in the control group.. Plasma
bevacizumab concentrations increased in the treatment
group from an average of 30.2 ± 15.0 μg/ml on day 2 to
56.4 ± 2.3 μg/ml on day 6 and 61.5 ± 16.6 μg/ml on day 10.
Bevacizumab concentrations were inversely correlated with
Figure 4. (A) Maximum uptake values of FMISO (y-axis) vs the day of treatment (x-axis). (B) Maximum uptake values of FDG (y-axis) vs the day of treatment
(x-axis). Maximum FDG uptake at day 10 was signiﬁcantly lower in the bevacizumab group (white bars) than in the control group (grey bars; p=0.01). (C)
AUC180 values (y-axis) vs the day of treatment (x-axis). The AUC180 values decreased over time in both treatment and control group. (D) Boxplot of the mean
T2* values (y-axis) vs the day of treatment (x-axis). The T2* values increased over time. The rise was more pronounced in the control group (0.45, p= 0.01).
Figure 5. Example of a vital non-necrotic area of (A) an untreated and (B) a bevacizumab-treated tumor 10 days after start of treatment showing the
combined image of hypoxia (pimonidazole, green), perfused vessels (Hoechst, blue) and vessels (9F1, red).
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the immunohistochemically determined vascular density
(r =0.45, p = 0.01) and positively correlated with CAIX
expression in the tumor (r = 0.77, p = 0.02). Bevacizumab levels
did not correlate to imaging parameters.
4. DISCUSSION
In this study, functional imaging techniques were used to assess
tumor hypoxia and vascularity after bevacizumab treatment. The
FMISO PET imaging technique indicating hypoxia did not show
an increase in hypoxia after bevacizumab treatment. In fact,
FMISO PET even showed a trend toward a lower FMISO uptake
in bevacizumab treated tumors, suggesting a decrease in
hypoxia. However, the lower T2* values measured with MRI in
the bevacizumab-treated group pointed toward a higher
deoxyhemoglobin concentration and thus hypoxia or a lower
blood volume. Also, although pimonidazole binding in
bevacizumab-treated tumors did not increase signiﬁcantly, we
observed a marked increase in the hypoxia-related metabolic
parameters CAIX and GLUT1 in bevacizumab-treated tumors.
Furthermore, the level of bevacizumab in the blood of the mice
was inversely correlated to CAIX expression, suggesting a
stronger effect with longer and higher dose exposition. Finally,
we observed an inverse correlation between CAIX and vascular
density. Thus, these data suggest that bevacizumab treatment
increases hypoxia in the tumor, which, however, could not be
detected by FMISO PET or pimonidazole staining.
There remains the question of how the conﬂict of data should
be interpreted. It is relevant to note that all the techniques that
used injected tracers to measure tumor hypoxia failed to show
an increase in tumor hypoxia after bevacizumab treatment, while
techniques based on intrinsic tumor properties did show an
increase in hypoxia. It could be hypothesized that tracer distribu-
tion in the tumor is affected by the effect of bevacizumab on the
number of functional vessels and vascular permeability. Previously,
anti-VEGF has been shown to diminish accumulation of several
macromolecules (trastuzumab, anti-EGFR and anti-IGF-1R anti-
bodies) and of chemotherapy (31–33). Moreover, the combination
of chemotherapy, cetuximab and bevacizumab led to detrimental
outcome in colorectal cancer patients (34), which in part might be
due to this phenomenon. The effect of bevacizumab on tumor
accumulation of small molecules, such as FMISO, FDG and
pimonidazole, is unknown. However, our data also suggest that
the uptake of small molecules may be hampered by bevacizumab
treatment. Therefore, the interval of 60min for FMISO scanning
may have been too short to reliably detect hypoxia. FMISO imag-
ing in patients generally requires a 2–3h is generally faster than
in humans, and shorter intervals have been described (36), our
FMISO results may reﬂect not only tumor hypoxia, but also tumor
vascular supply. In our study, higher blood levels of bevacizumab
were associated with lower tumor vascular density. Similarly, in a
study monitoring the vascular effects of the vascular disrupting
agent (5,6-dimethylxanthenone-4-acetic acid), a marked decrease
in FMISO uptake was observed in several tumors, together with a
decreased perfusion (36).
In the literature contradictory results have been reported
concerning the effect of bevacizumab on tumor hypoxia. In various
studies it has been reported that bevacizumab treatment resulted
in vascular normalization. In two studies in murine melanoma and
glioma models, treatment with bevacizumab decreased the
hypoxic fraction measured with pimonidazole, and increased
radiosensitivity (37,38). A study in patients with hepatic liver me-
tastases of colorectal cancer who were treated with neoadjuvant
chemotherapy and bevacizumab also showed that bevacizumab
treatment resulted in tumor vessel stabilization, leading to more
mature, stable vessels with an increased diameter, while decreas-
ing the vascular density and increasing necrosis (39). In contrast,
several studies showed an increase in pimonidazole positive areas
after bevacizumab treatment (40–42). In the literature, hypoxic
areas indicated by pimonidazole and CAIX seem to increase after
bevacizumab administration, although pimonidazole staining
yielded some conﬂicting results (35–40). The conﬂicting results
using pimonidazole staining support the hypothesis that intravas-
cular tracers might be less reliable after administration of
bevacizumab, suggesting that delivery of the tracer might be
affected. Pimonidazole does not increase, while hypoxia indeed
increases owing to bevacizumab treatment.
However, we did not observe a drop in the perfusion marker
Hoechst in the bevacizumab treated group. In line with this inter-
pretation, DCE-MRI parameters AUC90 and AUC180 were not signif-
icantly different between the treated and untreated groups,
despite the observed decrease in vascular density in the immuno-
histochemical analysis of the bevacizumab-treated tumors. These
data are in contrast to the theory that bevacizumab signiﬁcantly
hampered the vascular supply of systemically administered tracers.
Figure 6. (A) Mean GLUT1 and CAIX staining in the control group and
bevacizumab group at day 10. The difference in GLUT1 and CAIX expression
differed signiﬁcantly. (B) An example of an untreated tumor in the control
group with low CAIX expression (green) and a high vascular density (red)
and (C) an example of a treated tumor in the bevacizumab group of a tumor
with a high CAIX expression and a low vascular density.
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Alternative explanations for the conﬂicting results between
HIF-1 upregulated markers GLUT1 and CAIX, and pimonidazole
and FMISO, are the different pO2 levels at which CAIX is up-reg-
ulated and nitroimidazoles are reduced. CAIX and GLUT1 up-reg-
ulation probably starts at a higher pO2 level than that at which
nitromidazoles are reduced (43). Therefore, a small reduction in
pO2 levels caused by bevacizumab treatment might increase
CAIX expression without affecting pimonidazole and FMISO
uptake. Furthermore, bevacizumab might cause tumor cells to
switch toward a more glycolytic, anaerobic metabolism, decreas-
ing the aerobe metabolism and need for oxygen. This implies
that these cells could have a high expression of GLUT-1 and
CAIX, in order to allow for the high inﬂux of glucose and efﬂux
of the H+ ions needed for glycolysis, without an increase in
hypoxia. Enhanced expression of the endogenous hypoxia
marker CAIX was observed after bevacizumab administration in
previous studies, and is believed to be a mechanism of resistance
to bevacizumab treatment (44). Two studies showed that
bevacizumab efﬁcacy increased by inhibiting CAIX or the HIF-1
pathway (41,45).
In conclusion, in this study, bevacizumab treatment induced
shorter T2* times on MR imaging, a higher fraction of the intrinsic
hypoxia markers GLUT1 and CAIX on immunohistochemical
staining, and a decreased vascular density, suggesting an in-
crease in tumor hypoxia -and glycolysis- mediated by a decrease
in tumor vascularity. This could be a mechanism of resistance to
bevacizumab. The increase in hypoxia, however, could not be
demonstrated by pimonidazole or FMISO, possibly because the
distribution of these tracers is hampered by the effects of
bevacizumab on vascular permeability and perfusion.
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